Outlook Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Outlook Therapeutics (OTLK).

Price Target Range — 12 Quarters

Analyst Consensus — 7 Analysts

4Buy

3Hold

Consensus RatingBuy# Analysts7Avg. Consensus PT$10Upside to Avg. PT+1957.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 11, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$10→$11
Aug 14, 2026	BTIG	Julian Harrison	Maintained	Buy	$4
Jul 27, 2026	HC Wainwright & Co.	Douglas Tsao	PT Raise	Neutral	$1→$2
Jul 27, 2026	BTIG	Julian Harrison	Upgrade	Neutral→Buy	$4
Jun 11, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$6→$10
May 18, 2026	BTIG	Julian Harrison	Downgrade	Buy→Neutral	—
Mar 11, 2026	Ascendiant Capital	Edward Woo	PT Cut	Buy	$10→$6
Feb 18, 2026	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$1
Feb 18, 2026	Chardan Capital	Daniil Gataulin	Maintained	Neutral	$1
Jan 5, 2026	Chardan Capital	Daniil Gataulin	PT Cut	Neutral	$3→$1
Jan 2, 2026	HC Wainwright & Co.	Douglas Tsao	PT Cut	Neutral	$1→$1
Dec 22, 2025	Ascendiant Capital	Edward Woo	PT Raise	Buy	$8→$10
Sep 30, 2025	HC Wainwright & Co.	Douglas Tsao	Maintained	Neutral	$1
Sep 22, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$21→$8
Aug 29, 2025	Guggenheim	Eddie Hickman	Downgrade	Buy→Neutral	—
Aug 29, 2025	HC Wainwright & Co.	Douglas Tsao	Downgrade	Buy→Neutral	$1
Aug 28, 2025	Chardan Capital	Daniil Gataulin	Maintained	Neutral	$3
Aug 15, 2025	Chardan Capital	Daniil Gataulin	Maintained	Neutral	$3
Jun 6, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$24→$21
Feb 24, 2025	Ascendiant Capital	Edward Woo	PT Cut	Buy	$33→$24

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.

Benzinga Newsdesk

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

U.S. stocks fell, but S&P 500 gained 0.4% for 3rd week. Wall Street analysts make new stock picks daily, Benzinga's data can help make better trades.

Avi Kapoor

PRO
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.

Benzinga Newsdesk

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.

Benzinga Newsdesk

This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday

Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analyst ratings page before buying.

Avi Kapoor

Outlook Therapeutics Inc

Outlook Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

PRO
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PRO
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday

People Also Watch

People Also Watch

Outlook Therapeutics Inc

Outlook Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAscendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In

PROBTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

PROHC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6

This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5

PRO
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target

PRO
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6